RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.
9 Mar, 2022 | 08:22h | UTC
Commentary on Twitter
Trastuzumab dramatically improves outcome of HER2-positive breast cancer, though its high price limits access. HD201 is a biosimilar tested vs trastuzumab in HER2-positive early breast cancer, showing equivalence in pathologic complete response rates https://t.co/CycdYdXpMC #BCSM
— JAMA Oncology (@JAMAOnc) March 4, 2022